Stock Performance and Market Context
On 22 April 2026, Fredun Pharmaceuticals Ltd recorded a new 52-week and all-time high of Rs. 2,141, outperforming its sector by 3.03% and opening the day with a gap up of 2.4%. The stock’s intraday high represented a 4.75% increase, closing with a day change of 2.51%, while the Sensex declined by 0.84% on the same day. This bullish momentum is further supported by the stock trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling strong technical strength.
Long-Term Returns and Relative Strength
Fredun Pharmaceuticals has demonstrated exceptional long-term performance, delivering a staggering 15,093.26% return over the past decade compared to the Sensex’s 204.24%. Over five years, the stock surged 387.36%, significantly outpacing the Sensex’s 63.49% gain. The company’s three-year return of 139.80% also surpasses the Sensex’s 31.77%, while the one-year return of 206.31% contrasts with the Sensex’s slight decline of 1.24%. Year-to-date, the stock has gained 32.75%, outperforming the Sensex’s negative 7.76% performance. These figures underscore Fredun Pharmaceuticals’ sustained ability to generate market-beating returns across multiple time horizons.
Financial Growth and Profitability Metrics
The company’s financial trajectory has been marked by healthy growth rates. Net sales have expanded at an annual compound growth rate of 38.09%, while operating profit has grown even more rapidly at 58.31%. The latest quarterly results, declared in December 2025, were very positive, with net sales reaching Rs. 160.93 crores, a 56.70% increase year-on-year. Operating profit before depreciation and interest (PBDIT) hit a record Rs. 26.34 crores, and profit before tax excluding other income (PBT less OI) reached its highest level at Rs. 14.00 crores. The company has reported positive results for seven consecutive quarters, reflecting consistent operational strength.
Valuation and Quality Assessment
Fredun Pharmaceuticals is currently classified as a micro-cap stock with a market capitalisation grade reflecting this status. The stock trades at a price-to-earnings (P/E) ratio of 35x and a price-to-book value (P/BV) of 7.19x. Its enterprise value to capital employed ratio stands at 4.05x, indicating a fair valuation relative to its capital base. The PEG ratio of 0.61x suggests the stock is reasonably valued considering its earnings growth. Dividend yield remains modest at 0.03%, with a recent dividend payout of Rs. 0.7 per share and a payout ratio of 2.11%.
Quality metrics present a mixed but generally positive picture. The company is rated as average in overall quality, with excellent growth but below-average capital structure. Key indicators include a five-year sales growth rate of 38.09% and EBIT growth of 58.31%. However, leverage ratios such as average net debt to equity at 1.03 and debt to EBITDA at 2.89 indicate moderate to high leverage. Return on capital employed (ROCE) averages 14.74%, while return on equity (ROE) is 13.09%, both considered modest. Importantly, there is no promoter share pledging, and promoter confidence is rising, with promoters increasing their stake by 1.11% in the previous quarter to hold 44.17% of the company.
Technical Indicators and Market Sentiment
The technical trend for Fredun Pharmaceuticals is firmly bullish, with the trend having shifted from mildly bullish to bullish on 9 April 2026 at a price of Rs. 1,830. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal bullish momentum on both weekly and monthly timeframes. Immediate support is identified at the 52-week low of Rs. 635.05, while resistance levels have been surpassed, including the 20-day moving average at Rs. 1,770.25 and the 100-day moving average at Rs. 1,678.86. Delivery volumes have also increased significantly, with a 1-month delivery change of 60.76% and a 1-day delivery change of 23.02% compared to the 5-day average, indicating strong investor participation.
Promoter Confidence and Market Positioning
Promoter stake increase to 44.17% reflects growing confidence in the company’s prospects. This rise in promoter holding is often viewed as a positive signal, reinforcing the company’s stable ownership structure. Fredun Pharmaceuticals is also part of the MomentumNow thematic list on MarketsMOJO since 16 December 2025, and its Mojo Score has improved to 74.0 with a recent upgrade from Hold to Buy on 13 April 2026, highlighting the company’s improving fundamentals and market standing.
Summary of Key Financial and Market Metrics as of 22 April 2026
Price: Rs. 2,095.15
Market Cap Grade: Micro-cap
P/E Ratio (TTM): 35x
P/BV: 7.19x
EV/EBITDA: 15.59x
EV/Capital Employed: 4.05x
PEG Ratio: 0.61x
Dividend Yield: 0.03%
Promoter Holding: 44.17%
Mojo Score: 74.0 (Buy, upgraded from Hold)
Conclusion
Fredun Pharmaceuticals Ltd’s achievement of an all-time high price of Rs. 2,141 on 22 April 2026 is a testament to its sustained financial growth, improving market sentiment, and strong technical positioning. The company’s consistent quarterly performance, robust sales and profit growth, and rising promoter confidence have underpinned this milestone. While valuation metrics suggest a fair price relative to growth, the stock’s long-term returns have significantly outpaced broader market indices, reflecting its strong market presence within the Pharmaceuticals & Biotechnology sector.
